Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SOGUG Multidisciplinary Expert Panel Consensus on Updated Diagnosis and Characterization of Prostate Cancer Patients.

Current oncology (Toronto, Ont.)·2026
Same author

Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Advances in laboratory medicine·2025
Same author

Comparison of four different analyzers for prenatal trisomy 21 risk.

Advances in laboratory medicine·2025
Same author

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial.

Nature communications·2025
Same author

Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations.

Cancers·2025

Related Experiment Video

Updated: May 14, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Liquid Biopsy in Advanced Prostate Cancer.

Pilar Mediavilla-Medel1, Natalia García-Simón1, Aránzazu González-Del-Alba2

  • 1Liquid Biopsy Laboratory, Department of Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, 28222 Majadahonda, Spain.

Cancers
|May 13, 2026
PubMed
Summary
This summary is machine-generated.

Liquid biopsy offers a minimally invasive way to track prostate cancer. Advances in circulating tumor DNA (ctDNA) and other biomarkers improve personalized treatment and monitoring.

Keywords:
BRCAbiomarkerscell-free DNAcirculating tumor DNAcirculating tumor cellsextracellular vesiclesliquid biopsyprostate cancer

More Related Videos

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

Related Experiment Videos

Last Updated: May 14, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization
07:34

Enhancing Prostate Tumor Biobanking Reliability with Improved Sampling Technique and Histological Characterization

Published on: November 17, 2023

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

Area of Science:

  • Oncology
  • Molecular Diagnostics

Background:

  • Prostate cancer presents challenges due to heterogeneity and bone metastases, making tissue biopsy difficult.
  • Circulating biomarkers are crucial for managing prostate cancer, offering a less invasive alternative.
  • Liquid biopsy enables dynamic characterization of tumor biology, crucial for personalized medicine.

Purpose of the Study:

  • To review the role and advancements of liquid biopsy in prostate cancer management.
  • To highlight the clinical utility of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs).
  • To discuss challenges and emerging techniques in liquid biopsy for prostate cancer.

Main Methods:

  • Review of current literature on liquid biopsy techniques in prostate cancer.
  • Analysis of circulating tumor DNA (ctDNA) for actionable alterations (e.g., BRCA1/2, ATM mutations).
  • Evaluation of circulating tumor cells (CTCs) and extracellular vesicles (EVs) for tumor insights.
  • Exploration of emerging methods like fragmentomics and methylation profiling.

Main Results:

  • ctDNA analysis supports targeted therapy selection and monitoring of treatment response/resistance.
  • CTCs and EVs provide complementary information on tumor biology and progression.
  • Challenges include sensitivity in low tumor burden and confounding factors like clonal hematopoiesis (CH).
  • Newer approaches like fragmentomics and methylation profiling show promise in enhancing tumor specificity.

Conclusions:

  • Liquid biopsy, particularly ctDNA, is becoming integral to personalized prostate cancer management.
  • Integration of liquid biopsy aids in longitudinal monitoring and treatment adaptation.
  • Overcoming current limitations with emerging techniques will further enhance liquid biopsy's clinical utility in prostate cancer.